Importantly, although invasion and metastatic incidence and events were increased in SPARC−/− compared to SPARC+/+ mice, as previously reported [23], [26], losartan normalized tumor progression in SPARC−/− mice to the equivalent of that observed in SPARC+/+ counterparts (Table 2 and 3). This evidence concerns the gene SPARC and neoplasm.